Omalizumab: new addition to dermatologic therapy for chronic spontaneous/idiopathic urticaria
DOI:
https://doi.org/10.66344/jpad.25.4.2015.139References
Zuberbier T, Aberer W, Asero R et al. The EAACI/ GA(2)LEN/ EDF/ WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868- 87
Urgert MC, van den Elzen MT, Knulst AC et al. Omalizumab in patients with spontaneous urticaria: a systemic review and GRADE assessment. Br J Dermatol. 2015;173:404-415.
Saini SS, Bindslev-Jensen C, Maurer M et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/ spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67-75.
Maurer M, Rosen K, Hsieh H-J et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35.
Kaplan A, Ledford D, Ashby M et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101-9.
Saini S, Rosen KE, Hsieh H-J et al. A randomized, placebo-controlled, doseranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-73.e1.
Maurer M, Altrichter S, Bieber T et al. Efficacy and safety of omalizumab patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128:202-9.e5.
Kaplan A, Ferrer M, Bernstein JA et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2015 Oct 16. pii: S0091- 6749(15)01247-6. doi: 10.1016/j.jaci.2015.08.023. [Epub ahead of print]
Casale TB, Bernstein JA, Maurer M et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3:743-5.
Xolair (omalizumab) prescribing information; 2014. Available from: http://www.gene.com/gene/products/informa tion/pdf/xolair-prescribing.pdf. Accessed on September 17, 2015.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
